Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Not Out Of The Dark Yet: UK’s NICE Turns Down Clinuvel’s Phototoxicity Drug Scenesse

Executive Summary

NICE has issued a preliminary assessment in which it recommends against public funding in England for Clinuvel’s novel drug Scenesse for the ultra-rare condition, erythropoietic protoporphyria (EPP). The company says it intends to pursue reimbursement in the coming months.

You may also be interested in...



Keeping Track: A Week Of Calm As Shutdown Drags On

The latest drug development news and highlights from our US FDA Performance Tracker.

Will NICE Change Its Mind On Scenesse After UK Public Hearing?

This month should see the outcome of a public hearing held to discuss the decision by the UK's health technology assessment body, NICE, not to recommend funding for Clinuvel’s Scenesse, a novel treatment for the ultra-rare condition, erythropoietic protoporphyria.

Keeping Track: Pre-Independence Day Fireworks Crackle At US FDA With Burst Of Approvals And Filings

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Topics

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel